ClinicalTrials.gg
Sign In
RecruitingNCT07484971CLIQQCUpdated Apr 17, 2026

Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria

An observational study in Prostate Cancer, Prostate Cancer (Diagnosis) and Prostate Cancer (Post Prostatectomy), sponsored by Société Algérienne de Formation et Recherche en Oncologie. Recruiting at 24 sites in Algeria. Open to male participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Société Algérienne de Formation et Recherche en Oncologie · Observational

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 3 months later.
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
2,000
Ages
19 Years and older
Sex
Male
01

Study summary

The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with prostate cancer.

It also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.

Read the detailed description

This is a descriptive, cross-sectional clinical study including patients with histologically and/or biologically confirmed prostate cancer who are being followed in the participating centers. This study planned to enroll 500 patients.

Data will be collected from medical records and structured patient interviews (≈30 minutes). A standardized electronic case report form (eCRF) will be used to ensure completeness and reliability of the data. The variables studied will include sociodemographic data, medical history, clinical and biological characteristics of the disease, diagnostic examinations performed, and the therapeutic strategies implemented. All information will be anonymized and used exclusively for research purposes.

02

Conditions studied

  • Prostate Cancer
  • Prostate Cancer (Diagnosis)
  • Prostate Cancer (Post Prostatectomy)
  • Prostate Cancer Patients Treated by Radiotherapy
  • Prostate Cancer Metastatic
  • Prostate Cancer (Adenocarcinoma)

Keywords

  • oncology
  • patient outcome
  • Prostate Cancer
  • Prostate Cancer in Algerian patients
  • Observational Study
  • Retrospective data
  • Treatment strategies
  • Diagnostic approaches
  • Clinical characteristics
  • Epidemiological data
  • Demographic data
  • Cross-sectional study
  • Real-world data
  • Algeria
  • Algerian Study
03

In context

Prostatic Neoplasms

7,046 studies on the registry are indexed under Prostatic Neoplasms; 1,580 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 200 across 1,310 observational studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Société Algérienne de Formation et Recherche en Oncologie is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with histologically and/or biologically confirmed prostate cancer, followed in the participating centers.

Eligibility criteria

Inclusion Criteria:

  • Patients aged 19 years and older.
  • Diagnosis of prostate cancer confirmed histologically and/or biologically.
  • Patients followed in the participating oncology departments.
  • Written obtained.

Non Inclusion Criteria:

  • Histological types other than carcinoma
  • Secondary tumors
  • Participation in an interventional study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
2,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Socio-demographic characteristics of patients with prostate cancer in Algeria

    Frequency (%) of sociodemographic characteristics of patients with prostate cancer in Algeria, including age at diagnosis, marital status, and socioeconomic level.

    Time frame: At Baseline ( Initial visit )

  2. Personal and family history of cancer

    Frequency (%) of patients with personal and family history of cancer.

    Time frame: At Baseline (Initial Visit)

  3. Environmental and occupational exposures

    Frequency (%) of patients with environmental or occupational exposures.

    Time frame: At Baseline (Initial visit)

  4. Smoking history

    Frequency (%) of patients according to smoking status (current, former, never).

    Time frame: At Baseline (Initial visit)

  5. Alcohol consumption

    Frequency (%) of patients according to alcohol consumption (yes/no).

    Time frame: At Baseline (Initial visit)

  6. Initial symptoms and circumstances of diagnosis

    Frequency (%) of patients according to type of initial symptoms and circumstances of diagnosis.

    Time frame: At Baseline (Initial visit)

  7. International Prostate Symptom Score (IPSS)

    Distribution of patients according to the International Prostate Symptom Score (IPSS) at baseline. The IPSS is a validated questionnaire assessing the severity of lower urinary tract symptoms, with a total score ranging from 0 to 35, where higher scores indicate more severe (worse) symptoms.

    Time frame: At Baseline (Initial visit)

  8. Evolutionary status of patients

    Frequency (%) of patients according to disease status (in remission or with disease progression).

    Time frame: At Baseline (Initial visit)

Secondary outcomes

  1. Diagnosis by PSA testing

    % of patients diagnosed by PSA testing.

    Time frame: At Baseline (Initial visit)

  2. Diagnosis by imaging

    % of patients diagnosed by imaging.

    Time frame: At Baseline (Initial visit)

  3. Diagnosis by biopsy

    % of patients diagnosed by biopsy.

    Time frame: At Baseline (Initial visit)

  4. Time from symptom onset to first medical consultation

    Median time (in days) between onset of first symptoms and first medical consultation.

    Time frame: At Baseline (Initial visit)

  5. Time from first consultation to confirmed diagnosis

    Median time (in days) between first medical consultation and confirmed diagnosis.

    Time frame: At Baseline (Initial visit)

  6. Patients discussed in multidisciplinary team meetings

    % of patients discussed in tumor boards / multidisciplinary team meetings.

    Time frame: At Baseline (Initial visit)

  7. Initial treatment: Surgery

    % of patients receiving surgery as initial treatment.

    Time frame: At Baseline (Initial visit)

  8. Initial treatment: Radiotherapy

    % of patients receiving radiotherapy as initial treatment.

    Time frame: At Baseline (Initial visit)

  9. Initial treatment: Hormone therapy

    % of patients receiving hormone therapy as initial treatment.

    Time frame: At Baseline (Initial visit)

  10. Initial treatment: Active surveillance

    % of patients under active surveillance as initial management.

    Time frame: At Baseline (Initial visit)

  11. Time from diagnosis to treatment initiation

    Median time (in days) between diagnosis and treatment initiation.

    Time frame: At Baseline (Initial visit)

  12. Specialty of physician initiating treatment

    Medical specialty of the physician initiating treatment (urologist, oncologist, etc.).

    Time frame: At Baseline (Initial visit)

  13. Adverse events

    Frequency of adverse events by system/organ class and distribution according to severity grades (CTCAE grades 1 to 5).

    Time frame: At Baseline (Initial visit)

07

Study locations

21 of 24 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jul 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2025
First posted
Mar 20, 2026
StartActual
Jul 21, 2025
Primary completionEst.
Jul 21, 2026
CompletionEst.
Jul 21, 2026
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07484971
Lead sponsor
Société Algérienne de Formation et Recherche en Oncologie
Collaborators
ES Clinical Research, Ipsen, Astellas Pharma Inc
Responsible party
Sponsor
First posted
Mar 20, 2026
Start date
Jul 21, 2025
Primary completion
Jul 21, 2026 (estimated)
Completion
Jul 21, 2026 (estimated)
Last update
Apr 17, 2026

Study contacts

BOUNEDJAR ADDA, Professor
Contact
a_bounedjar@yahoo.fr
+213 25 20 90 72

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Prostatic Neoplasms →

Other studies from this sponsor

Société Algérienne de Formation et Recherche en Oncologie

Start the discussion